Turning Point Brands Inc (TPB) (Q3 2026) Earnings Call Highlights: Modern Oral Sales Double
Turning Point Brands Inc (TPB) reported Q3 2026 earnings, with adjusted EBITDA declining 41% YoY to $18M due to increased investments. Zig-Zag segment sales fell 15% YoY to $37M, while Stoker's gross margin decreased 416 bps. Modern Oral net revenue guidance for Q4 suggests potential sequential decline or slight increase. CEO David Glazek highlighted strong consumer adoption and positive retail distribution pipeline.
How this was made

The 30-second read
Why it matters
Traders can reassess near-term earnings quality (EBITDA down, margins pressured) versus medium-term growth drivers (Modern Oral adoption, retail chain store count expected to rise materially in 2026, and 2027 distribution/manufacturing optionality). FDA PMTA timing remains a key swing factor for when domestic manufacturing can improve margins.
Market read
The article provides actionable read-through on profitability pressure and the credibility of retail expansion plans, while emphasizing regulatory timing uncertainty for domestic manufacturing.
What to watch
PMTA dual-track strategy could reduce delay risk, but any FDA retesting requirement for the manufacturing-site change could still push timelines; also, Zig-Zag’s non-measured channel opacity may mask stabilization not captured in reported data.
Background
The piece summarizes Turning Point Brands’ Q3 2026 earnings call, focusing on Modern Oral, FRE/ALP retail rollout, Zig-Zag and Stoker’s segment performance, and FDA PMTA-driven manufacturing plans.
Ticker impact
Turning Point Brands reported Q3 call details including a 41% YoY decline in adjusted EBITDA to $18M and updated Modern Oral Q4 guidance.
Shares may face pressure from weaker EBITDA and segment declines, while stabilizing on retail wins and reiterated Modern Oral trajectory.
The article discloses multiple negative operating metrics (EBITDA down 41%, Zig-Zag net sales down 15%, margin down in Stoker’s) alongside management commentary that Modern Oral trajectory is unchanged and retail distribution should expand into 2026 and beyond, tempered by FDA PMTA-dependent manufacturing timing.
Market effects
Highlights ongoing regulatory and commercialization execution risk in nicotine pouch products tied to FDA PMTA pathways.
No clear regional market transmission beyond US FDA-dependent manufacturing timelines.
Limited, as the catalysts described are US regulatory and domestic retail distribution execution.
Counterpoint
The EBITDA decline may be largely investment-timing related, and the back-end loaded revenue cadence plus retail chain expansion could improve forward margins once domestic manufacturing ramps.
Key entities
- companyTurning Point Brands Inc
Subject of the earnings call highlights, including adjusted EBITDA decline, segment sales/margin changes, and Modern Oral Q4 guidance commentary.
- business_segmentModern Oral
Management reiterated the trajectory and discussed Q4 guidance cadence and retail distribution rollout dynamics.
- regulatoryFDA PMTA
Approval pathway that governs domestic manufacturing facility timing and a dual-track PMTA submission approach.



